Ranjith Kumavath | Drug Repurposing | Research Excellence Award

Research Excellence Award

Ranjith Kumavath
Affiliation Pondicherry University
Country India
Scopus ID 13907540500
Documents 98
Citations 1927
h-index 25
Subject Area Drug Repurposing
Event International Top Pharmaceutical Awards
ORCID 0000-0002-0751-5491

Ranjith Kumavath – Pondicherry University

Ranjith Kumavath of Pondicherry University is a researcher whose scholarly activities are associated with the field of drug repurposing, an interdisciplinary area that integrates pharmaceutical sciences, molecular biology, computational approaches, and translational medicine. This article presents a structured academic overview prepared in the style of a scholarly reference entry, highlighting research profile indicators, publication activity, research impact metrics, and considerations relevant to recognition through the Research Excellence Award at the International Top Pharmaceutical Awards.[1]

Abstract

This academic profile summarizes the scholarly record of Ranjith Kumavath, emphasizing research productivity, citation performance, and contributions within the domain of drug repurposing. Available bibliometric indicators indicate sustained publication activity and measurable scholarly influence through citations and an established h-index. The profile further examines research relevance, interdisciplinary engagement, and potential alignment with the objectives commonly associated with scientific recognition programs and research excellence awards.[1][2]

Keywords

Drug Repurposing; Pharmaceutical Research; Translational Medicine; Research Impact; Bibliometrics; Scopus; Scientific Publications; Citation Analysis; Academic Recognition; Research Excellence.

Introduction

Drug repurposing has emerged as an important strategy in modern pharmaceutical research due to its potential to identify new therapeutic applications for existing compounds while reducing development timelines and associated costs. Researchers working in this area frequently integrate experimental and computational methodologies to evaluate candidate molecules, biological targets, and disease mechanisms. Within this context, the academic record of Ranjith Kumavath reflects engagement with topics relevant to pharmaceutical innovation and translational research.[3]

Research Profile

According to the reported bibliometric indicators, the researcher has accumulated 98 indexed documents, 1,927 citations, and an h-index of 25. These indicators are commonly used to evaluate scholarly productivity and the influence of published work within academic literature.[1]

Research Contributions

The researcher’s contributions are associated with investigations involving therapeutic discovery, molecular mechanisms of disease, computational screening approaches, and the identification of alternative clinical applications for existing pharmaceutical compounds. Such work contributes to broader scientific efforts aimed at improving therapeutic efficiency and expanding treatment opportunities through evidence-based repurposing strategies.[3][2]

Publications

Publication activity constitutes an important component of academic evaluation. The available metrics indicate a substantial body of indexed scholarly work. Representative literature within the broader field of drug repurposing demonstrates the significance of systematic approaches for identifying therapeutic opportunities and validating candidate compounds through experimental and computational frameworks.[3]

Research Impact

Bibliometric indicators suggest that the researcher’s publications have been cited by subsequent scholarly works, indicating engagement with the scientific community and continued relevance within ongoing research discussions. Citation counts and h-index values are commonly considered alongside qualitative assessments when evaluating academic impact and research influence.[1][2]

Award Suitability

Academic awards commonly consider factors such as publication productivity, citation influence, research originality, interdisciplinary engagement, and contributions to scientific advancement. Based on the reported academic indicators, the profile demonstrates characteristics frequently reviewed during recognition processes. Final determinations regarding awards remain subject to the criteria, peer review procedures, eligibility requirements, and evaluation standards established by the awarding organization.[3]

Conclusion

Ranjith Kumavath’s academic profile reflects a documented record of research activity associated with drug repurposing and related pharmaceutical sciences. The available bibliometric indicators demonstrate established scholarly productivity and measurable citation impact. As a reference-style overview, this article summarizes key aspects of research performance, publication activity, and academic visibility relevant to scientific recognition and professional evaluation.[1]

References

  1. Elsevier. (n.d.). Scopus author details: Ranjith Kumavath, Author ID 13907540500. Scopus.
    https://www.scopus.com/authid/detail.uri?authorId=13907540500
  2. ORCID. (n.d.). ORCID record for Ranjith Kumavath.
    https://orcid.org/0000-0002-0751-5491
  3. P. V., Thomas, N. M., Ranjith, N. K., Muripiti, V., & Banothu, J. (n.d.). Pyrimidine derivatives as anti-HIV agents: Advances and structure–activity relationship insights.
    https://www.sciencedirect.com/science/article/abs/pii/S002228602601639X

Farha Naz | Drug Repurposing | Women Researcher Award

Dr. Farha Naz | Drug Repurposing | Women Researcher Award

Research Scientist at University of Virginia | United States

Dr. Farha Naz is a dynamic and accomplished structural biologist and immunologist, currently serving as a Research Scientist at the University of Virginia, USA. With a Ph.D. in Structural Biology from Jamia Millia Islamia, she has cultivated a distinguished research career focused on infectious diseases, host immunity, and vaccine development. Her postdoctoral work spans prestigious institutions including ICMR and UVA, and she has contributed to impactful translational research on Clostridioides difficile infection, tuberculosis, and host-pathogen interactions. Dr. Naz is also a frequent corresponding author and editorial contributor, demonstrating her leadership and scientific vision in global biomedical research.

Publication Profile 

Google Scholar

Education 

Dr. Farha Naz earned her Ph.D. in Structural Biology from Jamia Millia Islamia, New Delhi, graduating top of her batch in pre-PhD coursework. She completed her M.Sc. in Biotechnology in from Jamia Hamdard. Her B.Sc. from the University of Allahabad was marked by academic distinction, graduating. She completed her 12th and 10th at RDBIC, Allahabad. Her educational journey reflects academic excellence.

Experience 

Dr. Naz began her academic career as a Guest Faculty at the Centre of Bioinformatics, University of Allahabad. She later served as a Temporary Assistant Professor at SHUATS, Allahabad. she held a prestigious ICMR-Centenary Postdoctoral Fellowship at the National Institute of Pathology-ICMR in New Delhi. She then joined the University of Virginia as a Postdoctoral Research Associate in the Division of Infectious Diseases and International Health. Since February  she has been a Research Scientist in the same department, contributing to cutting-edge immunological and translational research in infectious diseases.

Awards and Honors 

Dr. Farha Naz has received multiple academic honors throughout her career. She was awarded the Junior Scientist Award by the Council of Science & Technology, U.P. She graduated as the Faculty Topper of her B.Sc. batch. She has qualified prestigious national fellowships and exams including the CSIR-UGC Fellowship in December, GATE in February, and the CSIR-UGC NET in June. These achievements highlight her consistent academic performance and her early recognition as a promising scientific talent. Her excellence continues through her high-impact research outputs and leadership roles in translational science.

Research Focus 

Dr. Naz’s research centers on host-pathogen interactions, mucosal immunology, and vaccine development, particularly against Clostridioides difficile and Mycobacterium tuberculosis. She investigates the mechanisms by which pathogens evade host immunity and how immune modulation can be leveraged for therapeutic interventions. Her work explores innate immune responses, cytokine signaling, GPCR modulation, and the role of sphingolipids in infection. She has contributed significantly to understanding vaccine adjuvants, humoral responses in recurrent infections, and therapeutic strategies involving immune and nervous system crosstalk. Her translational research aims to advance precision immunotherapy and infectious disease control globally.

Publication Top Notes

Investigation of molecular mechanism of recognition between citral and MARK4: A newer therapeutic approach to attenuate cancer cell progression

Microtubule affinity-regulating kinase 4: structure, function, and regulation

Elucidation of dietary polyphenolics as potential inhibitor of microtubule affinity regulating kinase 4: in silico and in vitro studies

Designing new kinase inhibitor derivatives as therapeutics against common complex diseases: structural basis of microtubule affinity-regulating kinase 4 (MARK4) inhibition

PKR-inhibitor binds efficiently with human microtubule affinity-regulating kinase 4

Battling COVID-19 pandemic: sphingosine-1-phosphate analogs as an adjunctive therapy?

Cloning, Expression, Purification and Refolding of Microtubule Affinity-Regulating Kinase 4 Expressed in Escherichia coli

Ubiquitin-associated domain of MARK4 provides stability at physiological pH

Atypical PKC phosphorylates microtubule affinity-regulating kinase 4 in vitro

Sphingosine-1-phosphate signaling in Leishmania donovani infection in macrophages

Evaluation of human microtubule affinity-regulating kinase 4 inhibitors: fluorescence binding studies, enzyme, and cell assays

Human microtubule affinity-regulating kinase 4 is stable at extremes of pH